Trial Profile
Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Angiotensin-1-7 (Primary)
- Indications Stem cell engraftment
- Focus Adverse reactions
- Sponsors Tarix Pharmaceuticals; US Biotest Inc
- 07 Dec 2020 Status changed from active, no longer recruiting to discontinued.
- 07 Dec 2020 Status changed from active, no longer recruiting to discontinued.
- 08 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Mar 2022.